Human Stem Cell Cloning: 'Holy Grail' or Techno-Fantasy?
By David King,
CNN
| 05. 17. 2013
(CNN) -- Today was a strange day. I'm used to handling the brief but overwhelming burst of media attention that comes with new stories about medical breakthroughs and ethical issues. But I don't often get an accompanying deluge of passionate e-mails and phone calls from people who had read my comments, denouncing me for criticizing science, especially medical research that "can save millions of lives."
There is definitely something special about this idea of "therapeutic cloning," something that has a religious feel to it. Most of those messages come from people who have family members suffering from some of the diseases that we are told will be cured, and it's hard to have to pour cold water on people's hopes.
I feel really angry at the scientists and PR people who have sold the idea of cloned human stem cells to so many patient support groups, when there is so little scientific substance to their promises. We are told that there will be great medical benefits and that the risks that there will be cloned babies are small, but in...
Related Articles
By Jacob M. Apel, The Baltimore Sun | 08.16.2024
By Neha Kondaveeti, The Austin Chronicle | 08.16.2024
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...